Connect with us
Between the high cost and testing hurdles, molnupiravir may not be the “game changer” against COVID. Read More
What motivation science has to say about goodbyes. Plus, GE’s $1.45 billion acquisition and monoclonal antibody bottleneck. Read More
Recent Comments